MIR195

Summary

MIR195 (microRNA 195, HGNC:31566) is a microRNA gene on chromosome 17p13.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406971 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31566
Approved symbol	MIR195
Name	microRNA 195
Location	17p13.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-195
Ensembl gene	ENSG00000284112
Ensembl biotype	miRNA
OMIM	610718
Entrez	406971
RNAcentral	URS000040EE1D — miRNA, 87 nt, 8 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385194

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385194 — 1 exons

Exon	Start	End
ENSE00001500200	7017615	7017701

Expression profiles

Bgee: expression breadth broad, 18 present calls, max score 69.34.

Top tissues by expression

18 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellum	UBERON:0002037	69.34	gold quality
omental fat pad	UBERON:0010414	68.94	gold quality
thyroid gland	UBERON:0002046	68.40	gold quality
endometrium	UBERON:0001295	68.09	gold quality
uterus	UBERON:0000995	68.06	gold quality
blood	UBERON:0000178	66.25	gold quality
pituitary gland	UBERON:0000007	64.10	gold quality
anterior cingulate cortex	UBERON:0009835	62.03	gold quality
testis	UBERON:0000473	60.39	gold quality
midbrain	UBERON:0001891	58.68	silver quality
skin of leg	UBERON:0001511	58.58	gold quality
ovary	UBERON:0000992	58.33	gold quality
left ovary	UBERON:0002119	58.31	gold quality
islet of Langerhans	UBERON:0000006	58.02	gold quality
spleen	UBERON:0002106	56.63	gold quality
epididymis	UBERON:0001301	55.15	silver quality
prostate gland	UBERON:0002367	54.22	gold quality
placenta	UBERON:0001987	54.07	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Show downregulation of miR-195 and miR-497 from the microRNA cluster site at chromosome 17p13.1 in primary peritoneal carcinoma relative to ovarian serous carcinoma. (PMID:18677302)
• study provides important roles of miR-195 in colorectal cancer pathogenesis and implicates its potential application in cancer therapy. (PMID:20727858)
• ET-1-mediated MIP-1beta gene expression is regulated via hypoxia-response elements, AP-1, and NF-kappaB cis-binding elements in its promoter and negatively regulated by microRNA-195, which targets the 3’ untranslated region of MIP-1beta RNA (PMID:20952681)
• both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets (PMID:21350001)
• Downregulation of miR-195 correlates with lymph node metastasis and colorectal cancer. (PMID:21390519)
• IFN-beta induces microRNA-195 expression and inhibits the cell proliferation by delaying G1 to S phase cell cycle progression in human hepatic stellate cell line LX-2. (PMID:21792910)
• miR-195 could improve the drug sensitivity at least in part by targeting Bcl-w to increase cell apoptosis in hepatocellular carcinoma cells. (PMID:21947305)
• Results identifyed three miRs, miR-451, miR-199a-3p and miR-195 to be predictive of recurrence of gastric cancer, with miR-451 having the strongest prognostic impact. (PMID:22046085)
• This work provides evidence for the initial mechanism by which miR-195 negatively regulates both the proliferation and invasion of glioblastoma cells, suggesting that the down-regulation of miR-195 might contribute to the malignant transformation of glioblastoma cells and could be a molecular signature associated with glioblastoma progression. (PMID:22217655)
• miR-195-5p is a novel and also the first identified miRNA that targets GLUT3, and the aberrant decreased expression of miR-195-5p and consequent GLUT3 up-regulation may contribute to bladder carcinogenesis. (PMID:22265971)
• identified CDK4, an early G1 cell cycle regulator, as a novel target of miR-195. Selective over-expression of miR-195 could induce G1-phase arrest in bladder cancer T24 cells, and subsequently inhibit T24 cell growth. (PMID:22289176)
• In HEK293 cells miR-195 might regulate the BACE1 mRNA translation or decay process, through the 3’-UTR binding site 1 without affecting transcription. (PMID:22721728)
• This is the first report on the function of miR-195 in human placental trophoblast cells which reveals an invasion-promoting effect of the small RNA via repressing ActRIIA. (PMID:22723898)
• MicroRNA-195 may have the potential to reduce neointimal formation in patients receiving stenting or angioplasty. (PMID:22802111)
• study shows WEE1 expression in malignant melanoma is directly regulated by miR-195; miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells (PMID:22847610)
• circulating miR-195 was higher in acute myocardial infarction patients than in controls at 4, 8, and 12 hours post-AMI. plasma concentration of miR-195 could be a potential indicator for AMI. (PMID:23236408)
• miR-195 and miR-378 are abnormally expressed and epigenetically regulated in gastric cancer cell lines and tissues via the suppression of CDK6 and VEGF signaling, suggesting that miR-195 and miR-378 have tumor suppressor properties in gastric cancer. (PMID:23333942)
• miR-195 plays an important role to inhibit the proliferation of glioma cells, and present a novel mechanism for direct miRNA-mediated suppression of cyclin D1 and cyclin E1 in glioma (PMID:23383003)
• Reduced miR-195 expression was associated with tumor size and the clinical stage of TSCC tumors. (PMID:23451060)
• MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. (PMID:23468064)
• miR-195 plays important inhibitory roles in cancer progression. miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. (PMID:23487264)
• over-expression of miR-195 sensitized resistant cells to DOX and enhanced cell apoptosis activity, all of which can be partly rescued by BCL2L2 siRNA and cDNA expression (PMID:23526568)
• These results suggest the molecular pathway regulating cell cycle progression to be integrally altered by downregulation of miR-195 and miR-497 expression, leading to the aberrant cell proliferation in hepatocarcinogenesis. (PMID:23544130)
• Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. (PMID:23756429)
• Expression of miR-195 or knockdown of Raf-1 can similarly reduce tumor cell survival. (PMID:23760062)
• MiR-195 regulates cell apoptosis in a context-dependent manner through directly targeting ARL2. (PMID:23807224)
• Ectopic expression of miR-195 in ESCC cells significantly downregulated Cdc42 by directly binding its 3’ untranslated regions, and induced G1 cell cycle arrest (PMID:24025765)
• Measuring plasma levels of miR-195 and miR-122 may especially be useful in EGFR mutant patients with lung adenocarcinoma (PMID:24282590)
• miR-195 plays important roles in regulating the functions of endometrial stromal cells by targeting fractalkine. (PMID:24294368)
• MiR-195-5p may act as a tumor suppressor in breast cancer. (PMID:24402230)
• findings indicated that miR-195 functions as tumour suppressor in NSCLC, and the miR-195/MYB axis might represent a potential therapeutic target for NSCLC intervention (PMID:24486218)
• Downregulation of miR-195/497 contributed to BC progression and metastasis. (PMID:24520312)
• miR-195 regulates SIRT1-mediated tissue damage in diabetic retinopathy (PMID:24570140)
• we found that MicroRNA-195 (miR-195) could negatively regulate protein levels of SRC-3 through targeting its 3’-untranslated region (3’-UTR) in hepatocellular carcinoma (HCC) cells (PMID:24740565)
• MiR195 has a suppressive role in colorectal cancer cells through directly targeting CARMA3. (PMID:24787958)
• Data indicate that insulin-like growth factor 1 receptor (IGF1R) was a target of miR-195 in non-small cell lung cancer (NSCLC)cells. (PMID:24874051)
• Data indicate that hepatoma-derived growth factor (HDGF) was a target of miR-195 in non-small cell lung cancer (NSCLC) cells. (PMID:24891187)
• Colonic tissue from patients with Hirschsprung’s disease showed increased expression levels of MIR195 which downregulated DIEXF. (PMID:25007945)
• ZNF367 is overexpressed in a variety of endocrine cancers and that it inhibits in vitro and in vivo growth, cellular invasion, migration, and adhesion. ZNF367 overexpression is associated with the loss of miR-195 expression. (PMID:25047265)
• The miR-195 in primary cardiomyocytes downregulates the expression of HMGA1 at the protein level. (PMID:25100012)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir457a	ENSDARG00000081987
mus_musculus	Mir195a	ENSMUSG00000065411
rattus_norvegicus	Mir195	ENSRNOG00000035638

Paralogs (3): MIR16-2 (ENSG00000198987), MIR15B (ENSG00000207779), MIR15A (ENSG00000283785)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.